Ligand Pharmaceuticals Incorporated

LGND

US53220K5048

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-16 EDT			5-day change	1st Jan Change
98.95 ^USD	+2.36%		+7.89%	+38.55%

07-10	Ligand Pharmaceuticals Incorporated Enters into First Amendment to Revolving Credit Facility	CI
07-08	Ligand to Acquire Apeiron for $100 Million in Cash, Plus Up to $28 Million Based on Royalties	MT

Tranche Update on Ligand Pharmaceuticals Incorporated's Equity Buyback Plan announced on September 24, 2018.

January 28, 2019 at 09:01 am

From October 1, 2018 to December 31, 2018, the company has repurchased 503,248 shares, representing 2.39% for $74.75 million. With this, the company has completed the repurchase of 503,248 shares, representing 2.39% for $74.75 million under the buyback announced on September 24, 2018.

Latest news about Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated Enters into First Amendment to Revolving Credit Facility	07-10	CI
Ligand to Acquire Apeiron for $100 Million in Cash, Plus Up to $28 Million Based on Royalties	07-08	MT
Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2024	07-08	CI
Ligand Pharmaceuticals Incorporated entered into an agreement to acquire APEIRON Biologics AG for $128 million.	07-07	CI
Invios GmbH announced that it expects to receive $4 million in funding from Ligand Pharmaceuticals Incorporated	07-07	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) added to Russell 2000 Defensive Index	06-30	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 3000 Growth Index	06-30	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) added to Russell 2000 Value-Defensive Index	06-30	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 3000E Growth Index	06-30	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 2000 Growth Index	06-30	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 2500 Growth Index	06-30	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell Small Cap Comp Growth Index	06-30	CI
Ligand Pharmaceuticals' Partner Gets US FDA Approval for Ohtuvayre to Treat Chronic Obstructive Pulmonary Disease	06-27	MT
Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals	06-18	MT
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE? (Pneumococcal 21-valent Conjugate Vaccine) for Adults	06-18	CI
Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing	05-13	MT
Tranche Update on Ligand Pharmaceuticals Incorporated's Equity Buyback Plan announced on August 8, 2023.	05-08	CI
Sector Update: Health Care Stocks Softer Late Afternoon	05-08	MT
Ligand Pharmaceuticals Shares Rise After Q1 Adjusted Earnings, Revenue Beat Views	05-08	MT
Transcript : Ligand Pharmaceuticals Incorporated, Q1 2024 Earnings Call, May 07, 2024	05-07
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q1 Revenue $31M, vs. Street Est of $27.9M	05-07	MT
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q1 EPS $1.20, vs. Street Est of $0.83	05-07	MT
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024	05-07	CI
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading	05-07	MT

Chart Ligand Pharmaceuticals Incorporated

Duration

Period

Chart Ligand Pharmaceuticals Incorporated

More charts

Company Profile

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.

Sector

Pharmaceuticals

Calendar

2024-08-04 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Ligand Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

98.95 USD

Average target price

117.8 USD

Spread / Average Target

+19.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIGAND PHARMACEUTICALS INCORPORATED	+38.55%	1.74B
ELI LILLY AND COMPANY	+61.53%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-3.66%	359B
MERCK & CO., INC.	+15.06%	325B
ABBVIE INC.	+9.18%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.67%	177B
PFIZER, INC.	+2.47%	165B

Other Pharmaceuticals

Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Pharmaceuticals

Tranche Update on Ligand Pharmaceuticals Incorporated's Equity Buyback Plan announced on September 24, 2018.

EPS Revisions